Tag Archives: biotechnology law

Shire v. Amneal Pharma – Adjusting the Rearview Mirror

Posted on September 30, 2015 by Warren Woessner

While the IP law world is being rocked by new developments in biosimilars, patent-eligible subject matter and IPR’s, it is almost refreshing to see a decision upholding the validity of claims to a “small molecule” drug based on application of … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , | 1 Comment

25 Critical Patentability & Validity Developments

Posted on September 28, 2015 by Warren Woessner

The Chisum Patent Academy is pleased to announce the September 2015 publication by Wolters Kluwer Law & Business of the annual Update for Volume I (Patentability and Validity) of the practitioner treatise, Mueller on Patent Law, authored by our co-founder, … Continue reading →

Posted in Miscellaneous | Tagged , , , , , | Leave a comment

Sandoz Launches First Biosimilar Drug in U.S.

Posted on September 4, 2015 by Warren Woessner

A new chapter in the generics/innovator wars began Thursday as Sandoz, Novartis’ generics division launched its Neupogen biosimilar, Zarxio, in the U.S. at about a 15-30% discount from the price of Neupogen. While biosimilars have been marketed in Europe since 2006, Congress … Continue reading →

Posted in Biosimilars | Tagged , , , , , , , , , , , | Leave a comment

Another Claim Bites the Dust left by Teva v. Sandoz

Posted on September 3, 2015 by Warren Woessner

Although the jury found the claims valid, and the Fed. Cir. affirmed, this decision, which found that the claims were not insolubly ambiguous, was revisited by the Fed. Cir. While there are pages on issue preclusion, in the end, the … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , | 2 Comments